COVID-19 mortality in cirrhosis is determined by cirrhosis-associated comorbidities and extrahepatic organ failure: Results from the multinational LEOSS registry.
ACLD
COVID-19
SARS-CoV-2
SBP
chronic liver disease
cirrhosis
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
17
01
2022
accepted:
11
04
2022
pubmed:
29
4
2022
medline:
18
5
2022
entrez:
28
4
2022
Statut:
ppublish
Résumé
International registries have reported high mortality rates in patients with liver disease and COVID-19. However, the extent to which comorbidities contribute to excess COVID-19 mortality in cirrhosis is controversial. We used the multinational Lean European Open Survey on SARS-CoV-2-infected patients (LEOSS) to identify patients with cirrhosis documented between March 2020 and March 2021, when the wild-type and alpha variant were predominant. We compared symptoms, disease progression and mortality after propensity score matching (PSM) for age, sex, obesity, smoking status, and concomitant diseases. Mortality was also compared with that of patients with spontaneous bacterial peritonitis (SBP) without SARS-CoV-2 infection, a common bacterial infection and well-described precipitator of acute-on-chronic liver failure. Among 7096 patients with SARS-CoV-2 infection eligible for analysis, 70 (0.99%) had cirrhosis, and all were hospitalized. Risk factors for severe COVID-19, such as diabetes, renal disease, and cardiovascular disease were more frequent in patients with cirrhosis. Case fatality rate in patients with cirrhosis was 31.4% with the highest odds of death in patients older than 65 years (43.6% mortality; odds ratio [OR] 4.02; p = 0.018), Child-Pugh class C (57.1%; OR 4.00; p = 0.026), and failure of two or more organs (81.8%; OR 19.93; p = 0.001). After PSM for demographics and comorbidity, the COVID-19 case fatality of patients with cirrhosis did not significantly differ from that of matched patients without cirrhosis (28.8% vs. 26.1%; p = 0.644) and was similar to the 28-day mortality in a comparison group of patients with cirrhosis and SBP (33.3% vs. 31.5%; p = 1.000). In immunologically naïve patients with cirrhosis, mortality from wild-type SARS-CoV-2 and the alpha variant is high and is largely determined by cirrhosis-associated comorbidities and extrahepatic organ failure.
Sections du résumé
BACKGROUND AND OBJECTIVE
International registries have reported high mortality rates in patients with liver disease and COVID-19. However, the extent to which comorbidities contribute to excess COVID-19 mortality in cirrhosis is controversial.
METHODS
We used the multinational Lean European Open Survey on SARS-CoV-2-infected patients (LEOSS) to identify patients with cirrhosis documented between March 2020 and March 2021, when the wild-type and alpha variant were predominant. We compared symptoms, disease progression and mortality after propensity score matching (PSM) for age, sex, obesity, smoking status, and concomitant diseases. Mortality was also compared with that of patients with spontaneous bacterial peritonitis (SBP) without SARS-CoV-2 infection, a common bacterial infection and well-described precipitator of acute-on-chronic liver failure.
RESULTS
Among 7096 patients with SARS-CoV-2 infection eligible for analysis, 70 (0.99%) had cirrhosis, and all were hospitalized. Risk factors for severe COVID-19, such as diabetes, renal disease, and cardiovascular disease were more frequent in patients with cirrhosis. Case fatality rate in patients with cirrhosis was 31.4% with the highest odds of death in patients older than 65 years (43.6% mortality; odds ratio [OR] 4.02; p = 0.018), Child-Pugh class C (57.1%; OR 4.00; p = 0.026), and failure of two or more organs (81.8%; OR 19.93; p = 0.001). After PSM for demographics and comorbidity, the COVID-19 case fatality of patients with cirrhosis did not significantly differ from that of matched patients without cirrhosis (28.8% vs. 26.1%; p = 0.644) and was similar to the 28-day mortality in a comparison group of patients with cirrhosis and SBP (33.3% vs. 31.5%; p = 1.000).
CONCLUSIONS
In immunologically naïve patients with cirrhosis, mortality from wild-type SARS-CoV-2 and the alpha variant is high and is largely determined by cirrhosis-associated comorbidities and extrahepatic organ failure.
Identifiants
pubmed: 35482663
doi: 10.1002/ueg2.12232
pmc: PMC9103364
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
409-424Informations de copyright
© 2022 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
Références
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Lancet Reg Health Eur. 2021 Nov 04;12:100240
pubmed: 34901909
Hepatol Int. 2020 Sep;14(5):612-620
pubmed: 32725453
Gastroenterology. 2020 May;158(6):1745-1761
pubmed: 31982413
J Hepatol. 2018 Aug;69(2):534-543
pubmed: 29753761
Infection. 2021 Feb;49(1):63-73
pubmed: 33001409
Sci Data. 2020 Dec 10;7(1):435
pubmed: 33303746
Gut. 2021 Oct;70(10):1914-1924
pubmed: 34281984
Front Med (Lausanne). 2021 Mar 12;8:626425
pubmed: 33777974
Liver Int. 2020 Jul;40(7):1792-1793
pubmed: 32436600
J Hepatol. 2021 May;74(5):1097-1108
pubmed: 33227350
Gut. 2022 May;71(5):1036-1038
pubmed: 35396231
Gastroenterology. 2021 Nov;161(5):1487-1501.e5
pubmed: 34284037
J Hepatol. 2020 Nov;73(5):1063-1071
pubmed: 32526252
J Hepatol. 2021 Mar;74(3):567-577
pubmed: 33035628
JHEP Rep. 2020 Oct;2(5):100146
pubmed: 32838246
J Hepatol. 2021 Feb;74(2):330-339
pubmed: 32781201
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
United European Gastroenterol J. 2022 May;10(4):409-424
pubmed: 35482663
J Hepatol. 2020 Oct;73(4):842-854
pubmed: 32673741
World J Gastroenterol. 2014 Mar 14;20(10):2542-54
pubmed: 24627590
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1469-1479.e19
pubmed: 32950749
J Hepatol. 2019 Apr;70(4):797-799
pubmed: 30635243
Gastroenterology. 2020 Aug;159(2):768-771.e3
pubmed: 32376408
Sci Rep. 2021 Jun 3;11(1):11734
pubmed: 34083670
Sci Rep. 2017 Jul 7;7(1):4914
pubmed: 28687809
Gut. 2021 Mar;70(3):531-536
pubmed: 32660964
Gastroenterology. 2019 Apr;156(5):1368-1380.e10
pubmed: 30552895
BMC Gastroenterol. 2013 Feb 07;13:25
pubmed: 23390924
Korean J Intern Med. 2021 Sep;36(5):1092-1101
pubmed: 34399573
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Ann Intern Med. 2020 Nov 17;173(10):855-858
pubmed: 32628537
J Hepatol. 2014 Dec;61(6):1385-96
pubmed: 25135860
Hepatology. 2016 Oct;64(4):1249-64
pubmed: 27483394
J Hepatol. 2018 Sep;69(3):718-735
pubmed: 29777749
Gastroenterology. 2010 Oct;139(4):1246-56, 1256.e1-5
pubmed: 20558165
PLoS One. 2021 Mar 4;16(3):e0247461
pubmed: 33661992
Nat Rev Gastroenterol Hepatol. 2021 May;18(5):348-364
pubmed: 33692570
J Hepatol. 2015 Apr;62(1 Suppl):S131-43
pubmed: 25920082